

CITATION REPORT

List of articles citing

The use of dendritic cells in cancer immunotherapy

DOI: 10.1016/s0952-7915(03)00015-3

Current Opinion in Immunology, 2003, 15, 138-47.

Source: <https://exaly.com/paper-pdf/35214029/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
559	Langerhans cells - dendritic cells of the epidermis. 2003 , 111, 725-40		189
558	Tumour immunology. <i>Current Opinion in Immunology</i> , 2003 , 15, 129-30	7.8	32
557	Cancer immunotherapy: simply cell biology?. 2003 , 9, 515-6		3
556	Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. 2003 , 14, 1511-24		31
555	Dendritic cell vaccination and immunostimulation in advanced melanoma. 2003 , 2, 825-33		4
554	Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. 2003 , 171, 5940-7		160
553	Antibody Response after Vaccination with Antigen-Pulsed Dendritic Cells. 2004 , 19, 213-220		0
552	Avances en inmunoterapia celular contra el melanoma maligno. 2004 , 132, 1115		
551	Cancer vaccines. 2004 , 8, 521-5		3
550	Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. 2004 , 15, 393-404		58
549	Adoptive Immunotherapy: Methods and Protocols. 2004 ,		
548	Novel peptide-based HIV-1 immunotherapy. 2004 , 4, 349-61		5
547	Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor. 2004 , 64, 8435-42		13
546	Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. 2004 , 199, 1503-11		100
545	Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. 2004 , 172, 2845-52		104
544	Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. 2004 , 64, 6783-90		105
543	Distinct transcriptional programs activated by interleukin-10 with or without lipopolysaccharide in dendritic cells: induction of the B cell-activating chemokine, CXC chemokine ligand 13. 2004 , 172, 7031-42		101

542	Generation of clinical-grade monocyte-derived dendritic cells using the CliniMACS system. 2005 , 109, 71-82	5
541	Anticancer vaccination strategies. 2004 , 15 Suppl 4, iv153-60	22
540	Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrier. 2004 , 14, 295	3
539	Phenotypic characterization and distribution of dendritic cells in parotid gland tumors. 2004 , 66, 313-9	3
538	New strategy for efficient selection of dendritic cell-tumor hybrids and clonal heterogeneity of resulting hybrids. 2004 , 3, 1145-51	6
537	Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. 2004 , 172, 4026-36	33
536	Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. 2004 , 101, 1291-6	94
535	Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. 2004 , 173, 2855-65	43
534	Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. 2004 , 172, 6281-9	74
533	Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. 2004 , 91, 1656-62	133
532	Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. 2004 , 10, 2891-901	113
531	Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. 2004 , 173, 2788-94	155
530	Lymphoid organ dendritic cells: beyond the Langerhans cells paradigm. 2004 , 82, 91-8	70
529	Thymus-leukemia antigen (TL) as a major histocompatibility complex (MHC) class Ib molecule and tumor-specific antigen. 2004 , 95, 469-74	3
528	Melanoma or not? Cancer testis antigens may help. 2004 , 151, 1213-8	33
527	Comparison of two mononuclear cell program settings on two apheresis devices intended to collect high yields of CD14+ and CD3+ cells. 2004 , 44, 1104-11	13
526	DC-SIGN-specific liposomal targeting and selective intracellular compound delivery to human myeloid dendritic cells: implications for HIV disease. 2004 , 59, 415-24	34
525	Dendritic cells: a journey from laboratory to clinic. 2004 , 5, 7-10	176

524	An innately interesting decade of research in immunology. 2004 , 10, 1307-20	111
523	Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. 2004 , 11, 317-24	29
522	Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization. 2004 , 11, 1048-56	16
521	Three-dimensional two-layer collagen matrix gel culture model for evaluating complex biological functions of monocyte-derived dendritic cells. 2004 , 287, 79-90	17
520	Apoptosis of monocytes and the influence on yield of monocyte-derived dendritic cells. 2004 , 294, 67-80	18
519	Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. 2004 , 14, 161-9	45
518	Folate-mediated targeting of T cells to tumors. 2004 , 56, 1219-31	27
517	Cellular immunotherapy with dendritic cells in cancer: current status. 2004 , 22, 501-13	42
516	Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. 2004 , 58, 862-70	893
515	Monitoring of CD4+ and CD8+ T-cell responses after dendritic cell-based immunotherapy using CFSE dye dilution analysis. 2004 , 24, 653-63	12
514	Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. 2004 , 53, 705-14	44
513	Determining control parameters for dendritic cell-cytotoxic T lymphocyte interaction. 2004 , 34, 2407-18	40
512	RNA-containing adenovirus/polyethylenimine transfer complexes effectively transduce dendritic cells and induce antigen-specific T cell responses. 2004 , 6, 464-70	7
511	Generation of leukemia-specific T-helper type 1 cells applicable to human leukemia cell-therapy. 2004 , 93, 17-25	4
510	T-cell clonotypes in cancer. 2004 , 2, 11	16
509	Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. 2004 , 2, 12	38
508	Evaluation of in vivo labelled dendritic cell migration in cancer patients. 2004 , 2, 27	92
507	Activated platelets rapidly up-regulate CD40L expression and can effectively mature and activate autologous ex vivo differentiated DC. 2004 , 6, 487-497	28

506	Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. 2004 , 331, 159-64	62
505	A novel phosphoprotein is induced during bone marrow commitment to dendritic cells. 2004 , 321, 26-30	5
504	Antigen delivery by dendritic cells. 2004 , 294, 337-44	26
503	OM-197-MP-AC adjuvant properties: the in vitro maturation of normal and leukemic dendritic cells in a serum-free culture model. 2004 , 209, 67-77	3
502	Gene expression profiling of dendritic cells by DNA microarrays. 2004 , 209, 155-61	12
501	DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. 2004 , 25, 659-64	68
500	A mathematical approach for optimizing dendritic cell-based immunotherapy. 2005 , 109, 19-34	5
499	Dendritic cells: immunobiology and cancer immunotherapy. 2004 , 20, 17-23	126
498	Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity. 2004 , 20, 47-58	45
497	What is new in melanoma research? Vaccines, Basic and Translational Research in 2003: report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003. 2004 , 14, 241-3	1
496	Dendritic cell activation kinetics and cancer immunotherapy. 2004 , 172, 2727-8	4
495	Immunological treatment of ovarian cancer. 2004 , 16, 87-92	21
494	Manipulating dendritic cell biology for the active immunotherapy of cancer. 2004 , 104, 2235-46	278
493	Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. 2004 , 103, 3076-83	39
492	Measuring melanoma-specific cytotoxic T lymphocytes elicited by dendritic cell vaccines with a tumor inhibition assay in vitro. 2005 , 28, 148-57	8
491	Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma. 2005 , 28, 158-68	30
490	Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. 2005 , 28, 505-16	115
489	The Pulmonary Dendritic/Langerhans Cell in Immunity and Disease. 2005 , 12, 84-89	1

488	Cellular adoptive immunotherapy after allogeneic stem cell transplantation. 2005 , 17, 617-21		20
487	Recent advances in immunotherapy of B-CLL using ex vivo modified dendritic cells. 2005 , 10, 189-203		2
486	Dendritic-cell activation by secretory phospholipase A2. 2005 , 105, 3583-7		23
485	Efficient migration of dendritic cells toward lymph node chemokines and induction of T(H)1 responses require maturation stimulus and apoptotic cell interaction. 2005 , 106, 1734-41		30
484	Administration of dendritic cells in cancer nodules in hepatocellular carcinoma. 2005 , 14, 969		2
483	Functional characterization of monocyte-derived dendritic cells generated under serumfree culture conditions. 2005 , 99, 209-16		20
482	Dendritic-cell-based therapeutic vaccination against cancer. <i>Current Opinion in Immunology</i> , 2005 , 17, 163-9	7.8	165
481	Immunological techniques: ex vivo characterization of T cell-mediated immune responses in cancer. <i>Current Opinion in Immunology</i> , 2005 , 17, 419-22	7.8	8
480	Mononuclear cell variability and recruitment in non-cytokine-stimulated donors after serial 10-liter leukapheresis procedures. 2005 , 45, 445-52		18
479	Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions. 2005 , 62, 86-98		21
478	Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions. 2005 , 62, 75-85		3
477	Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity. 2005 , 62, 45-54		95
476	In vivo veritas. 2005 , 23, 1372-4		6
475	Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. 2005 , 6, 1029-37		185
474	Immunosuppressive networks in the tumour environment and their therapeutic relevance. 2005 , 5, 263-74		1627
473	Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. 2005 , 12, 579-91		51
472	Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. 2005 , 19, 1621-7		93
471	[Vaccination therapy of melanoma]. 2005 , 3, 630-45		3

470	The cyclopentenone prostaglandin PGA2 costimulates the maturation of human dendritic cells. 2005 , 33, 144-50	7
469	An in vitro evaluation of the potential suitability of peripheral blood CD14(+) and bone marrow CD34(+)-derived dendritic cells for a tolerance inducing regimen in the primate. 2005 , 297, 237-52	18
468	FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells. 2005 , 302, 145-55	44
467	Maturation of dendritic cells in the presence of living, apoptotic and necrotic tumour cells derived from squamous cell carcinoma of head and neck. 2005 , 41, 17-24	12
466	Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. 2005 , 35, 66-75	68
465	Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients. 2005 , 115, 450-5	19
464	Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide. 2005 , 117, 265-73	30
463	Double-stranded secondary structures on mRNA induce type I interferon (IFN alpha/beta) production and maturation of mRNA-transfected monocyte-derived dendritic cells. 2005 , 7, 452-65	36
462	Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. 2005 , 54, 219-28	14
461	Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. 2005 , 54, 663-70	114
460	Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. 2005 , 54, 953-70	30
459	Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. 2005 , 23, 166-74	28
458	Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells. 2005 , 21, 7-18	19
457	Human dendritic cell subsets for vaccination. 2005 , 25, 551-72	77
456	Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. 2005 , 64, 323-31	9
455	Presence and maturity of dendritic cells in melanoma lymph node metastases. 2005 , 207, 83-90	18
454	Changes in the proteomic profile during differentiation and maturation of human monocyte-derived dendritic cells stimulated with granulocyte macrophage colony stimulating factor/interleukin-4 and lipopolysaccharide. 2005 , 5, 1186-98	50
453	. 2005 ,	6

452	. 2005 ,	3
451	Dendritic cells and HNSCC: A potential treatment option? (Review). 2005 , 13, 3	0
450	Optimizing the exogenous antigen loading of monocyte-derived dendritic cells. 2005 , 17, 621-35	18
449	Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. 2005 , 5, 7-22	11
448	Gene therapy and targeted toxins for glioma. <i>Current Gene Therapy</i> , 2005 , 5, 535-57	4-3 44
447	Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. 2005 , 78, 656-64	78
446	The Role of Chemokines and their Receptors in Tumor Progression and Invasion: Potential New Targets of Biological Therapy. 2005 , 1, 81-92	11
445	Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. 2005 , 11, 3446-54	14
444	Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. 2005 , 65, 10059-67	65
443	The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration. 2005 , 174, 3317-25	20
442	Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. 2005 , 171, 1168-77	89
441	Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. 2005 , 103, 156-64	54
440	Antisense therapy for restenosis following percutaneous coronary intervention. 2005 , 5, 79-89	15
439	Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. 2005 , 86, 241-305	123
438	Dendritic cells in allogeneic hematopoietic stem cell transplantation. 2005 , 46, 1387-96	13
437	RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: a quantitative analysis. 2005 , 12, 734-43	29
436	Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. 2005 , 174, 3087-97	120
435	The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant <i>Listeria monocytogenes</i> vaccine. 2005 , 175, 1983-90	85

434	Autoantigen-pulsed dendritic cells constitute a beneficial cytokine and growth factor network in ameliorating experimental allergic encephalomyelitis. 2005 , 11, 381-9	9
433	Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. 2005 , 11, 4955-61	76
432	Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses. 2005 , 174, 758-66	17
431	Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. 2005 , 16, 584-93	58
430	Tumor Immunology and Cancer Vaccines. 2005 ,	2
429	In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. 2005 , 11, 4495-503	82
428	High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. 2005 , 4, 289-94	34
427	Highlights from the 2005 American Society of Clinical Oncology Prostate Cancer Symposium, Orlando, Florida. 2005 , 3, 206-10	0
426	Highlights from the 41st Annual Meeting of the American Society of Clinical Oncology, May 2005, and the 2005 American Society of Clinical Oncology Prostate Cancer Symposium, February 2005, Orlando, Florida. 2005 , 4, 7-14	
425	Natural killer-dendritic cell cross-talk in cancer immunotherapy. 2005 , 5, 1303-15	87
424	Cancer immunotherapy based on killing of Salmonella-infected tumor cells. 2005 , 65, 3920-7	125
423	Strategies of tumor immune evasion. 2005 , 19, 347-54	97
422	Professional antigen-presentation function by human gammadelta T Cells. 2005 , 309, 264-8	511
421	The controversial abscopal effect. 2005 , 31, 159-72	187
420	Dendritic cells: limited potential in immunotherapy. 2005 , 37, 241-5	30
419	Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation. 2005 , 167, 1321-31	35
418	Monocyte enriched apheresis for preparation of dendritic cells (DC) to be used in cellular therapy. 2005 , 33, 165-73	7
417	Characterization of anti-self CD8 T-cell responses stimulated by recombinant Listeria monocytogenes expressing the melanoma antigen TRP-2. 2005 , 23, 4263-72	29

4 ¹⁶	Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. 2005 , 175, 2684-91	177
4 ¹⁵	Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency. 2005 , 7, R326-35	35
4 ¹⁴	Dendritic cell-based immunotherapy. 2006 , 25, 377-413	84
4 ¹³	Dendritic cell-based vaccination against cancer. 2006 , 20, 689-710	22
4 ¹²	Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. 2006 , 4, 36	35
4 ¹¹	Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. 2006 , 12, 869-77	135
4 ¹⁰	Fate of Chlamydomphila pneumoniae in human monocyte-derived dendritic cells: long lasting infection. 2006 , 40, 101-9	12
4 ⁰⁹	The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines. 2006 , 211, 127-36	32
4 ⁰⁸	Non-invasive imaging of dendritic cell migration in vivo. 2006 , 211, 587-97	27
4 ⁰⁷	Gammadelta T cells: an alternative type of professional APC. 2006 , 27, 112-8	60
4 ⁰⁶	Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. 2006 , 24, 1847-57	94
4 ⁰⁵	An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. 2006 , 24, 3477-89	40
4 ⁰⁴	Vaccination to treat noninfectious diseases: surveying the opportunities. 2006 , 289-317	
4 ⁰³	Antigen Presenting Cells as Drug Targets. 2006 , 539-584	
4 ⁰²	Trafficking of Dendritic Cells. 2006 , 184-215	1
4 ⁰¹	EpsteinBarr Virus. 897-914	
4 ⁰⁰	Epidermal Langerhans Cells. 73-100	2
3 ⁹⁹	Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity. 2006 , 108, 1298-305	23

398	Nucleic Acid Transfer. 1143-1171		2
397	A functional comparison of mature human dendritic cells prepared in fluorinated ethylene-propylene bags or polystyrene flasks. 2006 , 46, 1494-504		17
396	Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma. 2006 , 65, 215-22		22
395	Culture medium and protein supplementation in the generation and maturation of dendritic cells. 2006 , 63, 401-9		23
394	An essential role for Akt1 in dendritic cell function and tumor immunotherapy. 2006 , 24, 1581-90		84
393	Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination. 2006 , 13, 318-25		20
392	Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. 2006 , 13, 905-18		156
391	Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. 2006 , 126, 1804-12		38
390	Cellular and molecular mechanisms of liver tolerance. 2006 , 213, 101-18		194
389	Generation, migration and function of circulating dendritic cells. <i>Current Opinion in Immunology</i> , 2006 , 18, 503-11	7.8	102
388	Biophysical studies on the differentiation of human CD14+ monocytes into dendritic cells. 2006 , 45, 19-30		15
387	Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. 2006 , 36, 137-46		51
386	Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. 2006 , 55, 819-29		115
385	Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. 2006 , 55, 1209-18		100
384	Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells. 2006 , 55, 1384-95		55
383	Antitumor action and immune activation through cooperation of bee venom secretory phospholipase A2 and phosphatidylinositol-(3,4)-bisphosphate. 2006 , 55, 1374-83		47
382	[Molecular targeted therapy]. 2006 , 77, 1118-25		3
381	Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer. 2006 , 103, 142-8		39

380	Prospects for exosomes in immunotherapy of cancer. 2006 , 10, 376-88	125
379	Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. 2006 , 243, 30-40	21
378	Murine dendritic cells generated under serum-free conditions have a mature phenotype and efficiently induce primary immune responses. 2006 , 310, 1-11	14
377	Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes. 2006 , 308, 77-89	10
376	The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. 2006 , 36, 1124-35	63
375	IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. 2006 , 36, 2046-60	118
374	In vivo magnetic resonance imaging of dendritic cell migration into the draining lymph nodes of mice. 2006 , 36, 2544-55	86
373	From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy. 2006 , 8, 3-17	36
372	Generation of cell hybrids via a fusogenic cell line. 2006 , 8, 919-28	9
371	Evaluation of DNA vaccination with recombinant adenoviruses using bioluminescence imaging of antigen expression: impact of application routes and delivery with dendritic cells. 2006 , 8, 1243-50	20
370	Macrophages as stimulators of MART-1 27-35 epitope-specific human cytolytic T lymphocytes in vitro. 2006 , 73, 238-43	
369	Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. 2006 , 105, 41-50	30
368	An age-structured model of dendritic cell trafficking in the lung. 2006 , 291, L1038-49	6
367	Transposon-assisted cloning and traceless mutagenesis of adenoviruses: Development of a novel vector based on species D. 2006 , 80, 8100-13	29
366	Random migration precedes stable target cell interactions of tumor-infiltrating T cells. 2006 , 203, 2749-61	182
365	IFN-alpha promotes definitive maturation of dendritic cells generated by short-term culture of monocytes with GM-CSF and IL-4. 2006 , 80, 278-86	31
364	Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. 2006 , 66, 3513-22	28
363	Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. 2006 , 66, 7285-92	135

362	Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN. 2006 , 177, 6122-8	44
361	Tumor Immunology. 2006 , 825-871	
360	Targeted therapies in gynecologic cancers. 2006 , 6, 333-63	35
359	Induction of antitumor immunity by CTL epitopes genetically linked to membrane-anchored beta2-microglobulin. 2006 , 176, 217-24	18
358	Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. 2006 , 177, 3448-60	103
357	Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. 2006 , 66, 3205-13	69
356	Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap. 2006 , 13, 301-9	33
355	Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. 2006 , 95, 896-905	206
354	Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. 2006 , 176, 966-73	159
353	Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. 2007 , 178, 1534-41	109
352	A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10. 2007 , 179, 6009-15	30
351	Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. 2007 , 178, 1268-76	80
350	Colorectal cancer: new advances in immunotherapy. 2007 , 6, 11-7	8
349	Plasmacytoid dendritic cells from human lung cancer draining lymph nodes induce Tc1 responses. 2007 , 36, 360-7	28
348	Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. 2007 , 20, 88-104	29
347	Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. 2007 , 67, 1842-52	211
346	Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. 2007 , 13, 1857-67	109
345	Breast Cancer. 2007 ,	

344	Disarming dendritic cells: a tumor strategy to escape from immune control?. 2007 , 3, 411-22	7
343	Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. 2007 , 82, 1106-14	53
342	Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory. 2007 , 82, 829-38	40
341	Lipids in dendritic cell biology: messengers, effectors, and antigens. 2007 , 81, 154-60	14
340	Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. 2007 , 67, 10528-37	53
339	Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination. 2007 , 67, 8450-5	26
338	Stat3 as a potential target for cancer immunotherapy. 2007 , 30, 131-9	72
337	Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection. 2007 , 30, 663-74	49
336	Efficient chemokine-dependent migration and primary and secondary IL-12 secretion by human dendritic cells stimulated through Toll-like receptors. 2007 , 30, 312-22	40
335	Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applications. 2007 , 30, 634-43	5
334	The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization. 2007 , 25, 7145-52	77
333	Activated B cells mediate efficient expansion of rare antigen-specific T cells. 2007 , 68, 75-85	12
332	Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1. 2007 , 25, 2331-9	8
331	Optimizing dendritic cell-based immunotherapy for cancer. 2007 , 6, 333-45	25
330	mRNA transfection of DC in the immature or mature state: comparable in vitro priming of Th and cytotoxic T lymphocytes against DC electroporated with tumor cell line-derived mRNA. 2007 , 9, 587-92	5
329	Immunological Tolerance. <i>Methods in Molecular Biology</i> , 2007 ,	1.4
328	Dendritic cell vaccine strategies for renal cell carcinoma. 2007 , 7, 221-32	19
327	Tumor microenvironment and immune escape. 2007 , 16, 755-74, viii	75

326	Antigen-presenting particle technology using inactivated surface-engineered viruses: induction of immune responses against infectious agents. 2007 , 4, 32	3
325	Converging Cell Therapy with Biomaterials. 2007 , 591-609	2
324	Immune Escape: Immunosuppressive Networks. 2007 , 83-97	1
323	Development and Application of Mixed Vaccines in Renal Cell Carcinoma: Combining Autologous Tumor Cells with Dendritic Cells Derived from Autologous or Allogeneic Origin. 2007 , 48, 111	2
322	Immune responses to tumours: current concepts and applications. 163-198	
321	Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments. 2007 , 120, 1696-703	34
320	Vaccinia virus impairs directional migration and chemokine receptor switch of human dendritic cells. 2007 , 37, 954-65	23
319	Both Langerhans cells and interstitial DC cross-present melanoma antigens and efficiently activate antigen-specific CTL. 2007 , 37, 2657-67	34
318	Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan. 2007 , 37, 3381-92	37
317	Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors. 2007 , 5, 7	11
316	Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. 2007 , 14, 277-83	20
315	Combined treatment with intratumoral injection of dendritic cells and topical application of imiquimod for murine melanoma. 2007 , 32, 541-9	11
314	Dendritic cell subsets in health and disease. 2007 , 219, 118-42	330
313	In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients. 2007 , 122, 18-27	16
312	Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. 2007 , 125, 257-67	59
311	T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. 2007 , 56, 659-75	55
310	Antigen-independent immune responses after dendritic cell vaccination. 2007 , 56, 897-903	14
309	Current approaches in dendritic cell generation and future implications for cancer immunotherapy. 2007 , 56, 1513-37	130

308	The influence of different culture microenvironments on the generation of dendritic cells from non-small-cell lung cancer patients. 2007 , 55, 405-15	4
307	Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2. 2007 , 82, 151-61	33
306	Tumor-derived death receptor 6 modulates dendritic cell development. 2008 , 57, 777-87	17
305	Freeze-and-thaw-disrupted tumour cells impair the responsiveness of DC to TLR stimulation. 2008 , 38, 2740-50	7
304	The use of dendritic cells in cancer immunotherapy. 2008 , 65, 191-9	80
303	Cancer vaccines: accomplishments and challenges. 2008 , 67, 93-102	41
302	Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. 2008 , 15, 1257-70	85
301	Engineered lentivector targeting of dendritic cells for in vivo immunization. 2008 , 26, 326-34	174
300	The kiss of death by dendritic cells to cancer cells. 2008 , 15, 58-69	54
299	Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells. 2008 , 158, 921-9	31
298	Isolation and characterization of dendritic cells from common marmosets for preclinical cell therapy studies. 2008 , 123, 566-74	12
297	Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. 2008 , 127, 66-77	27
296	IFNalpha treatment generates antigen-presenting cells insensitive to atorvastatin inhibition of MHC-II expression. 2008 , 129, 350-9	5
295	Sustained GM-CSF and PEI condensed pDNA presentation increases the level and duration of gene expression in dendritic cells. 2008 , 132, 273-8	29
294	Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production. 2008 , 337, 97-105	34
293	Clinical investigations of Toll-like receptor agonists. 2008 , 17, 1051-65	65
292	Dendritic cell-based cancer vaccination: quo vadis?. 2008 , 7, 1041-53	19
291	Multicenter study on in vitro characterization of dendritic cells. 2008 , 10, 21-9	2

290 Dendritic Cells in Clinics. **2008,**

289 Novel therapeutic strategies for treating esophageal adenocarcinoma: the potential of dendritic cell immunotherapy and combinatorial regimens. **2008,** 69, 614-24 9

288 Late dendritic cells are still able to evoke a potent alloreactive CTL response. **2008,** 213, 51-64 2

287 Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors. **2008,** 8, 1728-36 18

286 Immunohistochemical tracking of an immune response in mammary Paget's disease. **2008,** 272, 206-20 5

285 Tumour immunity: effector response to tumour and role of the microenvironment. **2008,** 371, 771-83 415

284 Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent. **2008,** 181, 5296-305 27

283 Immunisation with α Gal₁PSyngeneic dendritic cells protects mice from tumour challenge. **2008,** 98, 784-91 2

282 Noninvasive imaging of dendritic cell migration into lymph nodes using near-infrared fluorescent semiconductor nanocrystals. **2008,** 22, 3908-18 72

281 Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo. **2008,** 181, 4495-506 42

280 Plasticity of dendritic cell function in response to prostaglandin E2 (PGE2) and interferon-gamma (IFN-gamma). **2008,** 83, 883-93 21

279 Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. **2008,** 68, 5965-71 66

278 Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. **2008,** 40, 108-16 30

277 Killer dendritic cells and their potential role in immunotherapy. **2008,** 40, 75-81 11

276 Dendritic cell based immunotherapy--a promising therapeutic approach for endocrine malignancies. **2008,** 40, 89-98 11

275 Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency. **2008,** 15, 1321-9 13

274 Amino acid-modified calcitonin immunization induces tumor epitope-specific immunity in a transgenic mouse model for medullary thyroid carcinoma. **2008,** 149, 5627-34 9

273 Tumor immunotherapy by epicutaneous immunization requires langerhans cells. **2008,** 180, 1991-8 81

272	Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1. 2008 , 112, 2817-25	31
271	Efficient stimulation of T cell responses by human IFN-alpha-induced dendritic cells does not require Toll-like receptor triggering. 2008 , 31, 466-74	10
270	Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells. 2008 , 31, 52-62	12
269	Dendritic cells: a critical player in cancer therapy?. 2008 , 31, 793-805	64
268	Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. 2008 , 31, 101-12	54
267	Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. 2008 , 18, 152-60	50
266	Heterospecific CD4 help to rescue CD8 T cell killers. 2008 , 181, 5974-80	17
265	Immunotherapy for Renal Cell Carcinoma. 2008 , 51, 569	
264	Fusion induced reversal of dendritic cell maturation: An altered expression of inflammatory chemokine and chemokine receptors in dendritomas. 2009 , 23,	
263	MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy. 2009 , 9, 344-52	7
262	CD4+ T cells have a key instructive role in educating dendritic cells in allergy. 2009 , 149, 1-15	6
261	Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. 2009 , 69, 2497-505	102
260	Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. 2009 , 15, 4382-90	63
259	Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. 2009 , 16, 233-40	21
258	In situ regulation of DC subsets and T cells mediates tumor regression in mice. 2009 , 1, 8ra19	184
257	Enhanced antigen presentation and CTL activity by transduction of mature rather than immature dendritic cells with octaarginine-modified liposomes. 2009 , 136, 79-85	10
256	Standards und Trends bei der Behandlung des malignen Melanoms. 2009 , 2, 101-113	
255	Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy. 2009 , 58, 1137-47	38

254	The immunosuppressive tumor microenvironment in hepatocellular carcinoma. 2009 , 58, 877-86	38
253	Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo. 2009 , 58, 901-13	15
252	Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. 2009 , 100, 1092-8	136
251	Infection-mimicking materials to program dendritic cells in situ. 2009 , 8, 151-8	327
250	Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytes. 2009 , 49, 536-47	20
249	Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. 2009 , 122, 58-67	51
248	Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. 2009 , 113, 1651-60	42
247	Transplantation of dendritic cells promotes functional recovery from spinal cord injury in common marmoset. 2009 , 65, 384-92	20
246	Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. 2009 , 5, 379-90	57
245	Immune therapy for cancer. 2009 , 27, 83-117	476
244	Dendritic Cells in Cancer. 2009 ,	1
243	Tumor vaccines for breast cancer. 2009 , 27, 361-8	33
242	Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines. 23-43	3
241	The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders. 2009 , 50, 427-36	8
240	Efficient activation of LRH-1-specific CD8+ T-cell responses from transplanted leukemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells. 2009 , 32, 539-51	11
239	Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity. 2009 , 113, 3017-26	55
238	Abscopal Effect of Radiation Therapy and Signal Transduction. 2010 , 5, 212-222	3
237	Conditioning of the injection site with CpG enhances the migration of adoptively transferred dendritic cells and endogenous CD8+ T-cell responses. 2010 , 33, 115-25	14

236	Toll-like receptor agonists: are they good adjuvants?. 2010 , 16, 382-91		115
235	The immune modulation of Clara cell-10 in human peripheral monocytes and dendritic cells. 2010 ,		
234	Monophosphoryl lipid A plus IFNgamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential. 2010 , 59, 1185-95		30
233	Optimization of leukocyte collection and monocyte isolation for dendritic cell culture. 2010 , 24, 130-9		29
232	Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. 2010 , 11, 228-37		28
231	Killing effect of interleukin-13 receptor alpha 2 (IL-13Ralpha2) sensitized DC-CTL cells on human glioblastoma U251 cells. 2010 , 263, 172-5		9
230	Parenchymal cells critically curtail cytotoxic T-cell responses by inducing Bim-mediated apoptosis. 2010 , 40, 966-75		3
229	Efficient generation of clinical-grade genetically modified dendritic cells for presentation of multiple tumor-associated proteins. 2010 , 50, 831-42		8
228	Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour. 2010 , 162, 75-83		23
227	Langerhans cells as targets for immunotherapy against skin cancer. 2010 , 88, 431-7		37
226	Multicomponent apheresis. 2010 , 5, 83-87		7
225	Tumor antigen presentation by dendritic cells. <i>Critical Reviews in Immunology</i> , 2010 , 30, 345-86	1.8	44
224	Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. 2010 , 185, 738-47		62
223	Immunologically active biomaterials for cancer therapy. 2011 , 344, 279-97		10
222	Cellular und Tissue Engineering. 2010 , 55, 1-69		2
221	Biorheological changes of dendritic cells at the different differentiation stages. 2010 , 46, 265-73		3
220	IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. 2010 , 185, 4223-32		23
219	Dendritic cell apoptosis: regulation of tolerance versus immunity. 2010 , 185, 795-802		84

218	Mikro- und Nanosysteme. 2010 , 55, 1-139	1
217	Dendritic cell vaccines for brain tumors. 2010 , 21, 139-57	40
216	Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation. 2010 , 8, 90	35
215	Impairment of in vitro generation of monocyte-derived human dendritic cells by inactivated human immunodeficiency virus-1: Involvement of type I interferon produced from plasmacytoid dendritic cells. 2010 , 71, 541-50	11
214	Phenotype of dendritic cells generated from peripheral blood monocytes of patients with ovarian cancer. 2010 , 42, 3301-5	3
213	Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens. 2010 , 28, 290-5	2
212	Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. 2010 , 22, 173-82	54
211	Two-step maturation of immature DCs with proinflammatory cytokine cocktail and poly(I:C) enhances migratory and T cell stimulatory capacity. 2010 , 28, 2877-86	19
210	Conjugation of HPV16 E7 to cholera toxin enhances the HPV-specific T-cell recall responses to pulsed dendritic cells in vitro in women with cervical dysplasia. 2010 , 28, 5828-36	13
209	Dendritic cells devoid of IL-10 induce protective immunity against the protozoan parasite <i>Trypanosoma cruzi</i> . 2010 , 28, 7407-13	13
208	Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. 2011 , 208, 2291-303	284
207	Granulocyte-macrophage colony-stimulating factor increases the proportion of circulating dendritic cells after autologous but not after allogeneic hematopoietic stem cell transplantation. 2011 , 13, 888-96	5
206	Cancer Immunology and Immunotherapy. 2011 ,	1
205	IFN- β boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity. 2011 , 216, 537-47	41
204	Dendritic cells matured by a prostaglandin E2-containing cocktail can produce high levels of IL-12p70 and are more mature and Th1-biased than dendritic cells treated with TNF- α or LPS. 2011 , 216, 649-62	29
203	Nattectin a fish C-type lectin drives Th1 responses in vivo: licenses macrophages to differentiate into cells exhibiting typical DC function. 2011 , 11, 1546-56	30
202	Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN- β -dependent mechanism. 2011 , 187, 6310-7	24
201	Effect of oxygen levels on the physiology of dendritic cells: implications for adoptive cell therapy. 2011 , 17, 910-6	8

200	Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells. 2011 , 52, 990-8	3
199	Lung cancer vaccines. 2011 , 17, 302-8	29
198	Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon- γ 2011 , 34, 65-75	133
197	Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency. 2011 , 165, 180-9	31
196	Dendritic cells and immunity against cancer. 2011 , 269, 64-73	114
195	Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon- γ -dependent response against B16F10-Nex2 melanoma. 2011 , 18, 110-22	15
194	Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma. 2011 , 18, 370-80	20
193	In Vivo Modulation of Dendritic Cells by Engineered Materials: Towards New Cancer Vaccines. 2011 , 6, 466-477	55
192	Histamine H(4) receptor antagonism inhibits allergen-specific T-cell responses mediated by human dendritic cells. 2011 , 651, 197-204	18
191	Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. 2011 , 138, 255-65	121
190	Translating tumor antigens into cancer vaccines. 2011 , 18, 23-34	148
189	Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine. 2011 , 5, 323-32	14
188	Migration and immunological reaction after the administration of GalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer. 2011 , 60, 207-15	26
187	Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activation. 2011 , 60, 1609-24	8
186	Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?. 2011 , 50, 235-47	24
185	Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. 2011 , 9, 178	52
184	Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. 2011 , 9, 223	26
183	Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis. 2011 , 3, 222-34	35

182	Tumor eradication by immunotherapy with biodegradable PLGA microspheres--an alternative to incomplete Freund's adjuvant. 2011 , 129, 407-16	29
181	Simultaneous in vivo tracking of dendritic cells and priming of an antigen-specific immune response. 2011 , 32, 6254-63	73
180	Modification of human embryonic stem cell-derived dendritic cells with mRNA for efficient antigen presentation and enhanced potency. 2011 , 6, 303-18	9
179	Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines. 2011 , 1, 66-75	28
178	ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. 2011 , 187, 55-63	83
177	Provision of continuous maturation signaling to dendritic cells by RIG-I-stimulating cytosolic RNA synthesis of Sendai virus. 2011 , 186, 1828-39	16
176	Coupling presentation of MHC class I peptides to constitutive activation of antigen-presenting cells through the product of a single gene. 2011 , 23, 453-61	10
175	Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. 2011 , 5, 265-314	27
174	Nasal submucosal administration of antigen-presenting cells induces effective immunological responses in cancer immunotherapy. 2011 , 72, 149-52	5
173	Engineering Interfaces for Infection Immunity. 2011 , 295-314	1
172	Harnessing dendritic cells for tumor antigen presentation. 2011 , 3, 2195-213	10
171	Langerhans cells from human cutaneous squamous cell carcinoma induce strong type 1 immunity. 2012 , 132, 1645-55	24
170	The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions?. 2012 , 19, 1771-9	22
169	Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. 2012 , 109, 2066-71	162
168	Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma. 2012 , 61, 1407-13	18
167	Immunotherapy of Cancer. 2012 , 391-414	12
166	Autologous dendritic cell vaccine for estrogen receptor (ER)/progesterin receptor (PR) double-negative breast cancer. 2012 , 61, 1415-24	41
165	Recent developments on immunotherapy for brain cancer. 2012 , 17, 181-202	50

164	Targeted nanotherapy for induction of therapeutic immune responses. 2012 , 18, 72-80		31
163	Nicotine stimulated bone marrow-derived dendritic cells could augment HBV specific CTL priming by activating PI3K-Akt pathway. 2012 , 146, 40-9		22
162	Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy. 2012 , 16, 2827-37		29
161	Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy. 2012 , 9, 45-53		13
160	Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review. 2012 , 4, 995-1009		7
159	Innate Immune Regulation and Cancer Immunotherapy. 2012 ,		3
158	CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. <i>PLoS ONE</i> , 2012 , 7, e44266	3-7	45
157	Abscopal Effect of Radiation Therapy: Current Concepts and Future Applications. 2012 ,		2
156	Immunocombination therapy for high-risk neuroblastoma. 2012 , 4, 163-74		11
155	Early exposure of interferon- γ inhibits signal transducer and activator of transcription-6 signalling and nuclear factor κ B activation in a short-term monocyte-derived dendritic cell culture promoting α 1-antitrypsin-regulatory dendritic cells. 2012 , 167, 447-58		12
154	Third generation dendritic cell vaccines for tumor immunotherapy. 2012 , 91, 53-8		42
153	Immunotherapy of cancer in 2012. 2012 , 62, 309-35		301
152	NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo. 2012 , 10, 30		35
151	A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. 2012 , 61, 373-84		69
150	Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. 2013 , 132, 967-77		72
149	Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. 2013 , 11, 148		19
148	Biodegradable particles as vaccine delivery systems: size matters. 2013 , 15, 85-94		153
147	Dendritic Cells (DC) Facilitate Detachment of Squamous Carcinoma Cells (SCC), While SCC Promote an Immature CD16(+) DC Phenotype and Control DC Migration. 2013 , 6, 41-55		11

146	Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. 2013 , 62, 285-97	90
145	The interplay between pathogen-associated and danger-associated molecular patterns: an inflammatory code in cancer?. 2013 , 91, 601-10	51
144	RNA pulsed dendritic cells: an approach for cancer immunotherapy. 2013 , 31, 1141-56	26
143	Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. 2013 , 62, 125-35	265
142	Maturation of human iDCs by IL-18 plus PGE2, but not by each stimulus alone, induced migration toward CCL21 and the secretion of IL-12 and IFN- γ 2013 , 218, 238-44	
141	Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. 2013 , 185, 904-11	16
140	PMA withdrawal in PMA-treated monocytic THP-1 cells and subsequent retinoic acid stimulation, modulate induction of apoptosis and appearance of dendritic cells. 2013 , 46, 328-47	27
139	Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs immunomodulatory compounds lenalidomide and pomalidomide. 2013 , 139, 377-85	61
138	Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells. 2013 , 45, e8	17
137	Differentiation and activation of equine monocyte-derived dendritic cells are not correlated with CD206 or CD83 expression. 2013 , 139, 472-83	15
136	Tumor cell lysates as immunogenic sources for cancer vaccine design. 2014 , 10, 3261-9	83
135	Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer. 2014 , 12, 353	19
134	RAB8A a new biomarker for endometrial cancer?. 2014 , 12, 371	6
133	Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors. 2014 , 6, 108-18	4
132	Mathematical Models of Tumor-Immune System Dynamics. <i>Springer Proceedings in Mathematics and Statistics</i> , 2014 ,	0.2 12
131	Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates. 2014 , 2, 404-9	7
130	Immunotherapy advances for glioblastoma. 2014 , 16, 1441-58	136
129	Hydrogels and scaffolds for immunomodulation. 2014 , 26, 6530-41	215

128	Dendritic cell-targeted vaccines--hope or hype?. 2014 , 14, 705-11	149
127	Vaccines against cancer: Despite setbacks, attempts to harness the patient's immune system to fight tumor cells show promise in clinical trials. 2014 , 15, 485-8	4
126	Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. 2014 , 74, 1670-81	82
125	Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling. 2014 , 50, 370-8	37
124	Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells. 2014 , 142, 396-405	16
123	Zoledronic acid causes T cells to target monocytes and down-modulate inflammatory homing. 2014 , 143, 539-49	14
122	[Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma]. 2015 , 112, 1017-21	15
121	PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. 2015 , 2015, 253191	34
120	Immunotherapy for Bone and Soft Tissue Sarcomas. 2015 , 2015, 820813	15
119	RNA-Based Vaccines in Cancer Immunotherapy. 2015 , 2015, 794528	113
118	A new method to monitor antigen-specific CD8+ T cells, avoiding additional target cells and the restriction to human leukocyte antigen haplotype. 2015 , 22, 516-20	3
117	Isolation of dendritic cells from umbilical cord blood using magnetic activated cell sorting or adherence. <i>Oncology Letters</i> , 2015 , 10, 67-70	2.6 3
116	The cysteine-rich core domain of REIC/Dkk-3 is critical for its effect on monocyte differentiation and tumor regression. 2015 , 33, 2908-14	10
115	First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. 2015 , 33, 2690-6	31
114	Vaccination of multiple myeloma: Current strategies and future prospects. 2015 , 96, 339-54	16
113	Venous thrombosis in inflammatory bowel disease. 2015 , 187, 55	
112	Effects of dendritic cells from hepatitis B virus transgenic mice-stimulated autologous lymphocytes on hepatitis B virus replication: a study on the impact of specific sensitized effector cells on in vitro virus replication. 2015 , 28, 85-92	3
111	Dendritic Cell Targeting Vaccines. 2015 , 597-659	

110	In vivo tracking and immunological properties of pulsed porcine monocyte-derived dendritic cells. 2015 , 63, 343-54		11
109	High-risk corneal allografts: A therapeutic challenge. 2016 , 6, 10-27		22
108	Current status and perspectives of immune-based therapies for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016 , 22, 253-61	5.6	32
107	Dendritic Cells in the Tumor Microenvironment. 2016 , 499-511		1
106	Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination. 2016 , 2016, 5740373		18
105	Immune Cells in Cancer Therapy and Drug Delivery. 2016 , 2016, 5230219		23
104	Induced Pluripotent Stem Cell as a New Source for Cancer Immunotherapy. 2016 , 2016, 3451807		8
103	Human Articular Chondrocytes Regulate Immune Response by Affecting Directly T Cell Proliferation and Indirectly Inhibiting Monocyte Differentiation to Professional Antigen-Presenting Cells. <i>Frontiers in Immunology</i> , 2016 , 7, 415	8.4	9
102	Model-based genotype-phenotype mapping used to investigate gene signatures of immune sensitivity and resistance in melanoma micrometastasis. <i>Scientific Reports</i> , 2016 , 6, 24967	4.9	14
101	The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. 2016 , 7, 13720		145
100	Effect of an immunomodulatory regimen for cancer prevention: A case report. 2016 , 5, 540-544		
99	mRNA Cancer Vaccines. <i>Recent Results in Cancer Research</i> , 2016 , 209, 61-85	1.5	28
98	Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy. 2016 , 11, 2699-2709		15
97	Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient. 2016 , 16, 591		15
96	The STEAP1(262-270) peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice--A new approach to immunotherapy against prostate carcinoma. 2016 , 76, 456-68		9
95	Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination. 2016 , 35, 18		17
94	Identification of proteins derived from <i>Listeria monocytogenes</i> inducing human dendritic cell maturation. 2016 , 37, 10893-907		3
93	Immune Response After Radiofrequency Ablation and Surgical Resection in Nonsmall Cell Lung Cancer. 2016 , 28, 585-592		26

92	Dendritic cell targeted vaccines: Recent progresses and challenges. 2016 , 12, 612-22		44
91	Gene Therapy for Neurological Disorders. 2016 ,		
90	Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. 2017 , 123, 3061-3072		52
89	Immunotherapy of Uveal Melanoma: Vaccination Against Cancer. <i>Methods in Molecular Biology</i> , 2017 , 1499, 273-278	1.4	4
88	RNA Vaccines. <i>Methods in Molecular Biology</i> , 2017 ,	1.4	3
87	Immune roles of dendritic cells in stem cell transplantation. 2017 , 31, e13090		1
86	An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol. 2017 , 292, 1-9		24
85	4.3 The Innate Response to Biomaterials. 2017 , 30-43		1
84	Vaccination to Treat Noninfectious Diseases. 2017 , 421-444		
83	4.21 Engineering Interfaces for Infection Immunity ?. 2017 , 381-403		
82	The combined magnetic field and iron oxide-PLGA composite particles: Effective protein antigen delivery and immune stimulation in dendritic cells. 2018 , 520, 101-111		21
81	Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. 2018 , 164, 38-53		90
80	Extra-Large Pore Mesoporous Silica Nanoparticles Enabling Co-Delivery of High Amounts of Protein Antigen and Toll-like Receptor 9 Agonist for Enhanced Cancer Vaccine Efficacy. 2018 , 4, 484-492		98
79	Defining a standard and weighted mathematical index for maturation of dendritic cells. 2018 , 153, 532-544		
78	Automated closed-system manufacturing of human monocyte-derived dendritic cells for cancer immunotherapy. 2018 , 463, 89-96		9
77	Photodynamic therapy reduces the inhibitory effect of osteosarcoma cells on dendritic cells by upregulating HSP70. <i>Oncology Letters</i> , 2018 , 16, 5034-5040	2.6	6
76	Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer. <i>Frontiers in Immunology</i> , 2018 , 9, 2021	8.4	17
75	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. 2018 , 10,		31

74	Latest development on RNA-based drugs and vaccines. 2018 , 4, FSO300		34
73	Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. 2018 , 78, 4045-4058		35
72	Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy. 2018 , 2018, 3982942		5
71	AG490 reverses phenotypic alteration of dendritic cells by bladder cancer cells. <i>Oncology Letters</i> , 2018 , 16, 2851-2856	2.6	3
70	Mathematical Immunology of Virus Infections. 2018 ,		27
69	A 3D Macroporous Alginate Graphene Scaffold with an Extremely Slow Release of a Loaded Cargo for In Situ Long-Term Activation of Dendritic Cells. 2019 , 8, e1800571		14
68	Unleashing Tumour-Dendritic Cells to Fight Cancer by Tackling Their Three AB: Abundance, Activation and Antigen-Delivery. 2019 , 11,		7
67	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. 2019 , 7, 109		65
66	Leishmania infantum LeIF and its recombinant polypeptides induce the maturation of dendritic cells in vitro: An insight for dendritic cells based vaccine. 2019 , 210, 20-28		4
65	Harnessing Dendritic Cells for Poly (D,L-lactide--glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy. <i>Frontiers in Immunology</i> , 2019 , 10, 707	8.4	23
64	Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach. 2019 , 85, 1670-1683		6
63	Effects of Culture Conditions on Sonoporation of Dendritic Cells. 2019 ,		1
62	Maturation of dendritic cells by maitake β glucan enhances anti-cancer effect of dendritic cell vaccination. 2019 , 67, 408-416		10
61	Outcomes of Posterior Thoracic Corpectomies for Metastatic Spine Tumors: An Analysis of 90 Patients. 2019 , 123, e371-e378		9
60	Optimizing immune cell therapies with artificial intelligence. 2019 , 461, 34-40		7
59	Hollow Mesoporous Silica Nanoparticles with Extra-Large Mesopores for Enhanced Cancer Vaccine. <i>ACS Applied Materials & Interfaces</i> , 2020 , 12, 34658-34666	9.5	27
58	CARs: Beyond T Cells and T Cell-Derived Signaling Domains. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
57	Engineered biomaterials for cancer immunotherapy. <i>MedComm</i> , 2020 , 1, 35-46	2.2	19

56	The abscopal effect 67 years later: from a side story to center stage. <i>British Journal of Radiology</i> , 2020 , 93, 20200042	3.4	36
55	Nanoparticles in cancer immunotherapies: An innovative strategy. <i>Biotechnology Progress</i> , 2021 , 37, e30708	3.7	4
54	Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 1758835920987056	5.4	1
53	Dendritic Cell-Based Immunotherapy in Lung Cancer. <i>Frontiers in Immunology</i> , 2020 , 11, 620374	8.4	11
52	Functional Ambivalence of Dendritic Cells: Tolerogenicity and Immunogenicity. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
51	In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. 2021 , 9,		5
50	The Crosstalk Between Dendritic Cells, Cytokine-Induced Killer Cells And Cancer Cells From The Perspective Of Combination Therapy. <i>Russian Open Medical Journal</i> , 2021 , 10,	1.6	
49	Cancer Vaccines: Promising Therapeutics or an Unattainable Dream. <i>Vaccines</i> , 2021 , 9,	5.3	5
48	An Update on Mesoporous Silica Nanoparticle Applications in Nanomedicine. <i>Pharmaceutics</i> , 2021 , 13,	6.4	13
47	Immunobiology of Melanoma. <i>Clinics in Plastic Surgery</i> , 2021 , 48, 561-576	3	1
46	Melanoma and nonmelanoma skin cancers and the immune system. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 624, 187-202	3.6	7
45	Trafficking of Dendritic Cells in the Tumor Environment. 2009 , 271-289		1
44	A Cellular Automata Model to Investigate Immune Cell-Tumor Cell Interactions in Growing Tumors in Two Spatial Dimensions. <i>Springer Proceedings in Mathematics and Statistics</i> , 2014 , 223-251	0.2	1
43	Balancing tolerance and immunity: the role of dendritic cell and T cell subsets. <i>Methods in Molecular Biology</i> , 2007 , 380, 25-46	1.4	11
42	Generation of stable Th1/CTL-, Th2-, and Th17-inducing human dendritic cells. <i>Methods in Molecular Biology</i> , 2010 , 595, 117-33	1.4	19
41	Therapeutic vaccination for the treatment of malignant melanoma. <i>Recent Results in Cancer Research</i> , 2007 , 176, 219-27	1.5	8
40	Cancer gene therapy. 2009 , 589-612		2
39	Progress on new vaccine strategies for the immunotherapy and prevention of cancer. <i>Journal of Clinical Investigation</i> , 2004 , 113, 1515-25	15.9	144

38	Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. <i>Journal of Clinical Investigation</i> , 2007 , 117, 3087-96	15.9	23
37	DC-based cancer vaccines. <i>Journal of Clinical Investigation</i> , 2007 , 117, 1195-203	15.9	447
36	Imaging of tumour response to immunotherapy. <i>European Radiology Experimental</i> , 2020 , 4, 2	4.5	42
35	A potential protein adjuvant derived from Mycobacterium tuberculosis Rv0652 enhances dendritic cells-based tumor immunotherapy. <i>PLoS ONE</i> , 2014 , 9, e104351	3.7	42
34	Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. <i>Critical Reviews in Immunology</i> , 2013 , 33, 1-21	1.8	36
33	On dendritic cell-based therapy for cancers. <i>Journal of Zhejiang University Science B</i> , 2005 , 6, 1-3		4
32	Gene therapy and targeted toxins for glioma. <i>Current Gene Therapy</i> , 2011 , 11, 155-80	4.3	57
31	Heat-shocked tumor cell lysate-pulsed dendritic cells induce effective anti-tumor immune response in vivo. <i>World Journal of Gastroenterology</i> , 2006 , 12, 473-8	5.6	16
30	Myeloid and plasmacytoid dendritic cell combined vaccines loaded with heat-treated tumor cell lysates enhance antitumor activity in murine lung cancer. <i>Oncology Letters</i> , 2021 , 21, 90	2.6	4
29	Mycobacterium abscessus D-alanyl-D-alanine dipeptidase induces the maturation of dendritic cells and promotes Th1-biased immunity. <i>BMB Reports</i> , 2016 , 49, 554-559	5.5	5
28	Dendritic Cells in Tumor Immunology. 2004 , 95-129		
27	Immunological Strategies to Fight Skin Cancer. 2004 , 745-770		
26	Novel Gene Therapeutic Approaches to Brain Cancer. 2006 , 229-264		
25	Effects of a Herbal Composition (HemoHIM) on the Activation of Dendritic Cells. <i>Journal of the Korean Society of Food Science and Nutrition</i> , 2006 , 35, 1322-1328	1.5	2
24	Tumor Vaccines for Breast Cancer. <i>Translational Medicine Series</i> , 2007 , 297-312		
23	Analysis of dendritic cells from common marmosets for the treatment of CNS injury. <i>Inflammation and Regeneration</i> , 2008 , 28, 174-180	10.9	
22	Dendritic Cells: Biological and Pathological Aspects. 2008 , 409-427		
21	Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines. <i>Oncology & Hematology Review</i> , 2009 , 58, 40-48	0.1	

- 20 Dendritic Cell Vaccines. **2010**, 267-276
- 19 Membranes, molecules and biophysics: enhancing monocyte derived dendritic cell (MDDC) immunogenicity for improved anti-cancer therapy. *Journal of Cancer Therapeutics & Research*, **2013**, 2, 20
- 18 Biophysical Characteristics of DCs in Tumor Microenvironment. *SpringerBriefs in Biochemistry and Molecular Biology*, **2015**, 25-53
- 17 Modelling of Experimental Infections. **2018**, 97-152
- 16 Immunotherapy with mRNA vaccination and immunomodulation nanomedicine for cancer therapy. **2019**, 551-600
- 15 Envisioning the Application of Systems Biology in Cancer Immunology. **2020**, 599-624
- 14 Dendritic Cells in Tumor Immunology. **2008**, 105-140
- 13 Cytokine therapy for cancer: antigen presentation. *Cancer Treatment and Research*, **2005**, 123, 249-66 3.5 2
- 12 Morphologie und Funktion des spezifischen Immunsystems. **2006**, 237-245
- 11 Immun- und Gentherapie bei malignen Erkrankungen. **2006**, 285-290
- 10 Genetic Immunotherapy Approaches. **2005**, 129-141 2
- 9 Chemokine and Receptor Expression in Tumor Progression. **2007**, 267-283
- 8 Cell-Based Vaccines for Renal Cell Carcinoma. **2008**, 475-488
- 7 Conference report--dendritic cells: myths and reality highlights from the annual meeting of the American Society for Cell Biology; December 13-17, 2003; San Francisco, California. *MedGenMed: Medscape General Medicine*, **2004**, 6, 28
- 6 Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. *Current Opinion in Investigational Drugs*, **2009**, 10, 526-35 4¹
- 5 Comparison of DNA- and mRNA-Transfected Mouse Dendritic Cells as Potential Vaccines against the Human Papillomavirus Type 16 associated Oncoprotein E7. *Antiviral Therapy*, **2008**, 13, 495-509 1.6 4
- 4 Haptoglobin Induces a Specific Proteomic Profile and a Mature-Associated Phenotype on Primary Human Monocyte-Derived Dendritic Cells. *International Journal of Molecular Sciences*, **2022**, 23, 6882 6.3 1
- 3 Construction of a T7 phage display nanobody library for bio-panning and identification of chicken dendritic cell-specific binding nanobodies. *Scientific Reports*, **2022**, 12, 4.9 0

- 2 Studying the importance of regulatory T cells in chemoimmunotherapy mathematical modeling and proposing new approaches for developing a mathematical dynamic of cancer. **2023**, 563, 111437 ○
- 1 Isolated Peptide from Spider Venom Modulates Dendritic Cells In Vitro: A Possible Application in Oncoimmunotherapy for Glioblastoma. **2023**, 12, 1023 ○